Skip to main content
SpringerLink
Log in

Letter regarding “MT1-MMP is not a good prognosticator of cancer survival: evidence from 11 studies” by Wu KP et al.

  • Commentary
  • Published:
Tumor Biology

The Original Article was published on 07 September 2014

Abstract

With great interest, we carefully read a meta-analysis entitled “MT1-MMP is not a good prognosticator of cancer survival: evidence from 11 studies” in Tumor Biology (by Wu KP et al.), in which the investigators aimed to assess the association between MT1-MMP expression and prognosis of patients with various types of cancers by calculating the pooled hazard ratio (HR) with corresponding 95 % confidence interval (95 % CI). They have reached an important conclusion that MT1-MMP overexpression indicated an unfavorable overall survival (OS) in cancers and the pooled HR (95 % CI) was 2.46 (95 % CI 1.75–3.47). In addition, subgroup analysis showed the HRs (95 % CI) were 3.73 (95 % CI 2.67–5.21) and 2.46 (95 % CI 1.69–3.59) for MT1-MMP in lung cancer and gastric cancer, respectively. Before these results can be accepted, we would like to address several concerns related to this meta-analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wu KP, Li Q, Lin FX, et al. MT1-MMP is not a good prognosticator of cancer survival: evidence from 11 studies. Tumour Biol. 2014;35(12):12489–95.

    Article  CAS  PubMed  Google Scholar 

  2. Yoshizaki T, Maruyama Y, Sato H, et al. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer. 2001;95(1):44–50.

    Article  CAS  PubMed  Google Scholar 

  3. Massi D, Franchi A, Ketabchi S, et al. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin. Hum Pathol. 2003;34(1):80–8.

    Article  CAS  PubMed  Google Scholar 

  4. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Geriatric Surgery, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China

    Chao Tu, Jianping Zhou & Lianwen Yuan

Authors
  1. Chao Tu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jianping Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lianwen Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lianwen Yuan.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tu, C., Zhou, J. & Yuan, L. Letter regarding “MT1-MMP is not a good prognosticator of cancer survival: evidence from 11 studies” by Wu KP et al.. Tumor Biol. 37, 5761–5763 (2016). https://doi.org/10.1007/s13277-016-4910-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-016-4910-8

Keywords

Search

Navigation